JP5392961B2 - イロペリドンの結晶を含有する注射用デポ製剤 - Google Patents
イロペリドンの結晶を含有する注射用デポ製剤 Download PDFInfo
- Publication number
- JP5392961B2 JP5392961B2 JP2004520629A JP2004520629A JP5392961B2 JP 5392961 B2 JP5392961 B2 JP 5392961B2 JP 2004520629 A JP2004520629 A JP 2004520629A JP 2004520629 A JP2004520629 A JP 2004520629A JP 5392961 B2 JP5392961 B2 JP 5392961B2
- Authority
- JP
- Japan
- Prior art keywords
- crystals
- depot
- preparation according
- iloperidone
- depot preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本発明は、血漿への結晶成分の放出および吸収が結晶サイズに関連し得るイロペリドン(iloperidone)またはその代謝物の結晶を含む注射用デポ製剤に関する。
ポリ(d,l−ラクチド−コ−グリコリド)ミクロスフェアからの活性薬剤の制御された放出およびラクチド使用の一般的な現状は文献「L. M. Sanders et al., J. of Pharm. Sci., 73, No. 9, Sept. (1984); Controlled Release of a Luteininizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres(黄体化ホルモン放出ホルモン誘導体のポリ(d,l−ラクチド−コ−グリコリド)ミクロスフェアからの制御された放出)」に記載されている。
本発明は平均粒子サイズ(X50値)が1〜200ミクロンである、イロペリドンまたはその代謝物またはその医薬上許容される塩、水和物、溶媒和物、多形体または立体異性体の結晶を含有する注射用デポ製剤を提供する。
を有し、X50値が1〜200ミクロンである結晶を含有する注射用デポ製剤を提供する。
図1は、イロペリドン結晶の顕微鏡写真である。格子の1辺は100ミクロンに等しい。
図2は、粉砕したイロペリドン結晶の顕微鏡写真である。格子の1辺は250ミクロンに等しい。
図3は、雌性ウサギにおいて所定時間内に16ミクロンおよび30ミクロンのX50値を有するイロペリドン結晶デポ製剤の平均血漿中濃度を示すグラフである。
図4は、雌性ウサギにおいて所定時間内に170ミクロンのX50値を有するイロペリドン結晶デポ製剤による平均血漿中濃度を示すグラフである。
イロペリドンは1−[4−[3−[4−(6−フルオロ−1,2−ベンズイソオキサゾール−3−イル)−1−ピペリジニル]プロポキシ]−3−メトシキフェニル]エタノンである。本明細書で使用する「イロペリドン」にはその塩、水和物、溶媒和物、無晶形物のような多形体および/または立体異性体も含まれる。イロペリドンの代謝物は1−[4−[3−[4−(6−フルオロ(d)イソオキサゾール−3−イル)ピペリジン−1−イル]プロポキシ]−3−メトシキフェニル]エタノールである。本明細書で使用する「イロペリドンの代謝物」には、その塩、水和物、溶媒和物、無晶形のような多形体および/または立体異性体のいずれも包含するものとする。
で示される。
(R)エナンチオマーは構造式(III):
(i)この結晶の血漿中への放出を結晶サイズに相関させることができること;
(ii)この結晶の血漿中への吸収を結晶サイズに相関させることができること;
(iii)この結晶の粒子サイズを結晶化技術および/または粉砕で制御できること;および
(iv)この結晶は保存に対して安定であり、またガンマ線照射のような滅菌操作に対して安定である。
Claims (18)
- 水性媒体に懸濁されたイロペリドンまたはその代謝物の結晶100〜750mgを含有する注射用デポ製剤であって、当該結晶の平均粒子サイズ(X50値)が16〜170ミクロンであり、精神疾患の患者に対して皮下または筋肉内注射により投与後、16〜30日間にわたって有効な処置量を提供する、デポ製剤。
- 水性媒体が水であり、結晶が構造式(I):
で示される化合物であって、当該結晶のX50値が16〜170ミクロンである、請求項1に記載のデポ製剤。 - 結晶が構造式(II):
- 結晶が構造式(III):
- 結晶が構造式(II):
- 結晶が針状晶、三方晶、正方晶、平板な棒状晶、立方体晶、平行六面体晶および板状針状晶から構成される群から選択される形態である、請求項1〜5のいずれかに記載のデポ製剤。
- 結晶のX50値が16〜70ミクロンである、請求項1〜6のいずれかに記載のデポ製剤。
- さらに界面活性剤、溶解剤、乳化剤、保存剤、等張剤、分散剤、湿潤剤、充填剤、溶媒、緩衝剤、安定化剤、滑沢剤、濃稠化剤およびこれらの組み合わせから構成される群から選択される追加的成分を含有する、請求項1〜7のいずれかに記載のデポ製剤。
- 界面活性剤がソルビタンの脂肪酸エステル、ホスファチド、ポリオキシエチル化ソルビタンモノオレエート、プロピレングリコールのポリオキシアルキレン誘導体、ポリオキシエチル化脂肪、ポリオキシエチル化オレオトリグリセリド、リノル化オレオトリグリセリド、ポリエチレンオキシドと脂肪アルコールとの縮合物およびアルキルフェノールから構成される群から選択される、請求項8に記載のデポ製剤。
- 界面活性剤がプロピレングリコールのポリオキシアルキレン誘導体である、請求項9に記載のデポ製剤。
- 界面活性剤の濃度が0.5〜10mg/mLの範囲内にある、請求項8〜10のいずれかに記載のデポ製剤。
- 濃稠化剤がカルボキシメチルセルロースナトリウム、ヒドロキシプロピルセルロース、カルボキシメチルセルロースカルシウムおよび交差結合カルボキシメチルセルロースから構成される群から選択される、請求項8に記載のデポ製剤。
- 濃稠化剤がカルボキシメチルセルロースナトリウムである、請求項12に記載のデポ製剤。
- 濃稠化剤の濃度が2〜25mg/mLの範囲内である、請求項8および12〜13のいずれかに記載のデポ製剤。
- 等張剤が塩化ナトリウムのような塩類およびデキストロース、マンニトールおよび乳糖のような糖類から構成される群から選択される、請求項8に記載のデポ製剤。
- 等張剤がマンニトールである、請求項15に記載のデポ製剤。
- 水性媒体に懸濁されたイロペリドンまたはその代謝物の結晶100〜750mgを含有する注射用デポ製剤の入った容器を含むパッケージであって、当該結晶のX50値が16〜170ミクロンであり、精神疾患の患者に対して皮下または筋肉内注射により投与後、16〜30日間にわたって有効な処置量を提供する、パッケージ。
- 水性媒体が水であり、結晶が構造式(I):
で示される化合物であって、当該結晶のX50値が16〜170ミクロンである、請求項17に記載のパッケージ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0216416.8A GB0216416D0 (en) | 2002-07-15 | 2002-07-15 | Organic compounds |
GB0216416.8 | 2002-07-15 | ||
PCT/EP2003/007619 WO2004006886A2 (en) | 2002-07-15 | 2003-07-14 | Injectable depot formulation comprising crystals of iloperidone |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010236087A Division JP5670698B2 (ja) | 2002-07-15 | 2010-10-21 | イロペリドンの結晶を含有する注射用デポ製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005533093A JP2005533093A (ja) | 2005-11-04 |
JP2005533093A5 JP2005533093A5 (ja) | 2006-08-24 |
JP5392961B2 true JP5392961B2 (ja) | 2014-01-22 |
Family
ID=9940486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004520629A Expired - Lifetime JP5392961B2 (ja) | 2002-07-15 | 2003-07-14 | イロペリドンの結晶を含有する注射用デポ製剤 |
JP2010236087A Expired - Lifetime JP5670698B2 (ja) | 2002-07-15 | 2010-10-21 | イロペリドンの結晶を含有する注射用デポ製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010236087A Expired - Lifetime JP5670698B2 (ja) | 2002-07-15 | 2010-10-21 | イロペリドンの結晶を含有する注射用デポ製剤 |
Country Status (16)
Country | Link |
---|---|
US (5) | US20050250813A1 (ja) |
EP (1) | EP1523335B1 (ja) |
JP (2) | JP5392961B2 (ja) |
AT (1) | ATE348635T1 (ja) |
AU (1) | AU2003281154B2 (ja) |
CA (1) | CA2492467C (ja) |
CY (1) | CY1106305T1 (ja) |
DE (1) | DE60310564T2 (ja) |
DK (1) | DK1523335T3 (ja) |
ES (1) | ES2279153T3 (ja) |
GB (1) | GB0216416D0 (ja) |
HK (1) | HK1076029A1 (ja) |
NZ (1) | NZ537598A (ja) |
PT (1) | PT1523335E (ja) |
WO (1) | WO2004006886A2 (ja) |
ZA (1) | ZA200410323B (ja) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1578664A (zh) | 2001-10-30 | 2005-02-09 | 诺瓦提斯公司 | 伊潘立酮和星状聚合物的贮库制剂 |
GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
PL1675573T4 (pl) | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
EP2479290B1 (en) | 2004-09-30 | 2020-08-19 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
US8198305B2 (en) | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
EP2170279B1 (en) | 2007-07-31 | 2017-12-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
WO2009036100A2 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
US8729100B2 (en) | 2007-12-13 | 2014-05-20 | Vanda Pharmaceuticals, Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
PT2222300E (pt) | 2007-12-13 | 2014-07-28 | Vanda Pharmaceuticals Inc | Método e composição para tratamento de uma condição mediada por recetores da serotonina |
WO2010031497A1 (en) * | 2008-09-19 | 2010-03-25 | Miklos Vertessy | New process for the preparation of iloperidone |
CN101822673B (zh) * | 2009-03-04 | 2013-09-18 | 北京德众万全药物技术开发有限公司 | 一种含有伊潘立酮的固体药物组合物 |
EP2453891A1 (en) | 2009-07-16 | 2012-05-23 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
US8802855B2 (en) | 2009-09-19 | 2014-08-12 | Zhejiang Huahai Pharmaceutical Co., Ltd. | Method for preparation of iloperidone and crystallization method thereof |
CN102030744B (zh) * | 2009-09-30 | 2013-04-17 | 天津药物研究院 | 伊潘立酮晶体、其制备方法及药物组合物 |
WO2011055188A1 (en) * | 2009-11-05 | 2011-05-12 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of iloperidone |
US20130004545A1 (en) * | 2009-12-23 | 2013-01-03 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
CN102108081A (zh) * | 2009-12-25 | 2011-06-29 | 重庆医药工业研究院有限责任公司 | 伊潘立酮的新晶型及其制备方法 |
EA025415B1 (ru) | 2010-01-11 | 2016-12-30 | Инотек Фармасьютикалз Корпорейшн | Комбинация, набор и способ снижения внутриглазного давления |
EP2569325A4 (en) | 2010-03-26 | 2013-10-09 | Inotek Pharmaceuticals Corp | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA) DERIVATIVES OR CPA PRODRUGS |
CN101822674B (zh) * | 2010-05-27 | 2015-03-11 | 北京德众万全医药科技有限公司 | 一种伊潘立酮药物组合物及其制备方法 |
KR101936968B1 (ko) * | 2010-10-18 | 2019-01-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 주사용 서방형 제제 |
WO2012063269A2 (en) | 2010-11-12 | 2012-05-18 | Cadila Healthcare Limited | Process for preparing iloperidone |
WO2012090138A1 (en) | 2010-12-27 | 2012-07-05 | Ranbaxy Laboratories Limited | Processes for the preparation of iloperidone |
CN102680636A (zh) * | 2011-03-11 | 2012-09-19 | 天津药物研究院 | 一种伊潘立酮原料药及其中间体的质量控制方法 |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
KR102317399B1 (ko) | 2012-01-26 | 2021-10-26 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일주기 리듬 장애의 치료 |
JP2015508751A (ja) | 2012-01-26 | 2015-03-23 | イノテック ファーマシューティカルズ コーポレイション | [(2r,3s,4r,5r)−5−(6−(シクロペンチルアミノ)−9h−プリン−9−イル)−3,4−ジヒドロキシテトラヒドロフラン−2−イル]メチルナイトレートの無水多形体及びその製造方法 |
CN102659771B (zh) * | 2012-04-18 | 2013-11-27 | 吉林三善恩科技开发有限公司 | 一种伊潘立酮药物共晶及其制备方法 |
CN102633786B (zh) * | 2012-04-18 | 2013-11-27 | 吉林三善恩科技开发有限公司 | 一种伊潘立酮药物共晶及其制备方法 |
RU2632889C2 (ru) | 2012-05-18 | 2017-10-11 | Ванда Фармасьютиклз Инк. | Метаболиты (1r-транс)-n-[[2-(2,3-дигидро-4-бензофуранил)циклопропил]-метил]пропанамида |
RU2748386C2 (ru) | 2012-12-18 | 2021-05-25 | Ванда Фармасьютиклз Инк. | Лечение расстройств циркадного ритма |
MX2015013234A (es) * | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
CN103599074A (zh) * | 2013-11-26 | 2014-02-26 | 重庆医药工业研究院有限责任公司 | 一种伊潘立酮缓释微球及其制备方法 |
EP3258935B1 (en) | 2015-02-17 | 2021-04-07 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
US11071728B2 (en) | 2015-12-11 | 2021-07-27 | Vanda Pharmaceuticals Inc. | Treatment of schizophrenia |
CN106831741B (zh) * | 2016-12-28 | 2019-08-23 | 北京医药集团有限责任公司 | 一种伊潘立酮超细粉体的制备方法 |
US10935106B2 (en) * | 2018-06-14 | 2021-03-02 | Serapid, Inc. | Block chain with monolithic links |
US20200171018A1 (en) * | 2018-12-04 | 2020-06-04 | Vanda Pharmaceuticals Inc. | Depot administration of iloperidone |
WO2020117901A1 (en) * | 2018-12-04 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Depot administration of iloperidone |
US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB216416A (en) | 1923-09-06 | 1924-05-29 | James Baker And Sons Ltd | Improvements in boots and shoes |
JPS53108940A (en) * | 1976-10-28 | 1978-09-22 | Hoechst France | Optically active nncarbethoxyyalphaa aminophenyl acetic acids * its preparation and its use for preparation of optically active alpha aminoophenylacetic acid |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
DE3345355A1 (de) * | 1983-12-15 | 1985-06-27 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester |
DE3511587A1 (de) * | 1985-03-27 | 1986-10-02 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Glykoester des estradiols und estriols |
US4886370A (en) | 1987-08-25 | 1989-12-12 | Nkk Corporation | Method for detecting a state of substance existing in pipe |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
DE69021645T2 (de) * | 1989-05-19 | 1996-02-22 | Hoechst Roussel Pharma | N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente. |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
DE69125035T2 (de) * | 1990-06-04 | 1997-07-10 | Schering Corp | Verfahren zur herstellung von interferon-alpha-2 kristallen |
CA2095499A1 (en) * | 1992-05-08 | 1993-11-09 | Petrus J. M. Van Den Oetelaar | Depot preparation |
CA2148823C (en) * | 1992-11-17 | 1999-03-09 | Welfide Corporation | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
PT729357E (pt) | 1993-11-19 | 2005-06-30 | Janssen Pharmaceutica Nv | 1,2-bwenzazoles microencapsulados |
US5902882A (en) * | 1996-04-17 | 1999-05-11 | Hoffmann-La Roche Inc. | Assymetric synthesis of azepines |
TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
PL337027A1 (en) * | 1997-05-26 | 2000-07-31 | Akzo Nobel Nv | Salts of aromatic sulphonic acids |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
DE19816070A1 (de) | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden |
HUP0103781A3 (en) | 1998-10-16 | 2003-09-29 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition |
US6509310B1 (en) | 2000-06-01 | 2003-01-21 | Huish Detergents, Inc. | Compositions containing α-sulfofatty acid esters and method of making the same |
WO2001092334A1 (en) | 2000-06-02 | 2001-12-06 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
DK2305656T3 (da) * | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
CN1578664A (zh) * | 2001-10-30 | 2005-02-09 | 诺瓦提斯公司 | 伊潘立酮和星状聚合物的贮库制剂 |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
-
2002
- 2002-07-15 GB GBGB0216416.8A patent/GB0216416D0/en not_active Ceased
-
2003
- 2003-07-14 ES ES03756455T patent/ES2279153T3/es not_active Expired - Lifetime
- 2003-07-14 NZ NZ537598A patent/NZ537598A/en not_active IP Right Cessation
- 2003-07-14 DK DK03756455T patent/DK1523335T3/da active
- 2003-07-14 WO PCT/EP2003/007619 patent/WO2004006886A2/en active IP Right Grant
- 2003-07-14 PT PT03756455T patent/PT1523335E/pt unknown
- 2003-07-14 CA CA2492467A patent/CA2492467C/en not_active Expired - Lifetime
- 2003-07-14 AU AU2003281154A patent/AU2003281154B2/en not_active Expired
- 2003-07-14 US US10/521,064 patent/US20050250813A1/en not_active Abandoned
- 2003-07-14 JP JP2004520629A patent/JP5392961B2/ja not_active Expired - Lifetime
- 2003-07-14 AT AT03756455T patent/ATE348635T1/de active
- 2003-07-14 EP EP03756455A patent/EP1523335B1/en not_active Expired - Lifetime
- 2003-07-14 DE DE60310564T patent/DE60310564T2/de not_active Expired - Lifetime
-
2004
- 2004-12-22 ZA ZA200410323A patent/ZA200410323B/en unknown
-
2005
- 2005-09-15 HK HK05108084A patent/HK1076029A1/xx not_active IP Right Cessation
-
2006
- 2006-12-29 CY CY20061101867T patent/CY1106305T1/el unknown
-
2008
- 2008-10-21 US US12/254,925 patent/US20090099232A1/en not_active Abandoned
-
2010
- 2010-10-21 JP JP2010236087A patent/JP5670698B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-12 US US13/106,417 patent/US8293765B2/en not_active Expired - Lifetime
-
2012
- 2012-02-21 US US13/401,310 patent/US8227488B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/618,753 patent/US8614232B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2003281154A1 (en) | 2004-02-02 |
NZ537598A (en) | 2006-07-28 |
AU2003281154B2 (en) | 2006-10-12 |
EP1523335B1 (en) | 2006-12-20 |
DE60310564D1 (de) | 2007-02-01 |
DK1523335T3 (da) | 2007-01-29 |
US8227488B2 (en) | 2012-07-24 |
US20090099232A1 (en) | 2009-04-16 |
JP2011016849A (ja) | 2011-01-27 |
CA2492467C (en) | 2010-03-16 |
CA2492467A1 (en) | 2004-01-22 |
ES2279153T3 (es) | 2007-08-16 |
US8293765B2 (en) | 2012-10-23 |
EP1523335A2 (en) | 2005-04-20 |
JP5670698B2 (ja) | 2015-02-18 |
PT1523335E (pt) | 2007-02-28 |
ZA200410323B (en) | 2006-06-28 |
ATE348635T1 (de) | 2007-01-15 |
GB0216416D0 (en) | 2002-08-21 |
US20050250813A1 (en) | 2005-11-10 |
US20130012542A1 (en) | 2013-01-10 |
DE60310564T2 (de) | 2007-10-04 |
US8614232B2 (en) | 2013-12-24 |
US20120156264A1 (en) | 2012-06-21 |
WO2004006886A2 (en) | 2004-01-22 |
JP2005533093A (ja) | 2005-11-04 |
US20110212141A1 (en) | 2011-09-01 |
WO2004006886A3 (en) | 2004-02-19 |
CY1106305T1 (el) | 2011-10-12 |
HK1076029A1 (en) | 2006-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5392961B2 (ja) | イロペリドンの結晶を含有する注射用デポ製剤 | |
JP3274687B2 (ja) | 9−ヒドロキシリスペリドン脂肪酸エステルの水性懸濁物 | |
US8722679B2 (en) | Controlled release sterile injectable aripiprazole formulation and method | |
ES2743706T3 (es) | Preparación inyectable | |
US20200163960A1 (en) | Injectable formulation | |
JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
JP2020530475A (ja) | 医薬組成物 | |
US20240165107A1 (en) | Long Acting Injectable Compositions of Cariprazine or its Pharmaceutically Acceptable Salts | |
TWI291463B (en) | Thiazolidinedione hydrochloride hydrate, pharmaceutical composition comprising the same and process for preparing the same | |
CN115776881A (zh) | 长效配制品 | |
US20150119386A1 (en) | Process for preparing opthalmic suspension of brinzolamide | |
BG107357A (bg) | Тиазолидиндионова сол за лечение hа захарен диабеt | |
US20240180903A1 (en) | Injectable pharmaceutical composition, preparation method therefor and use thereof | |
WO2022206447A1 (zh) | 一种鲁拉西酮可注射混悬液及其制备方法 | |
AU2016364380A1 (en) | Formulations for intravenous injection of danirixin | |
JP2024518225A (ja) | 医薬組成物及びアプレピタント注射液並びに凍結乾燥粉末注射剤 | |
JPH0789858A (ja) | 水溶液組成物 | |
TW201302756A (zh) | 含維生素c或其衍生物的替莫唑胺醫藥組成物及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060704 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100407 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100510 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100608 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130430 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130903 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131015 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5392961 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |